Stage III non-small-cell lung cancer
an overview of treatment options
Additional information
Authors
Petrella F.,
Rizzo S. M. R.,
Attili I.,
Passaro A.,
Zilli T.,
Martucci F.,
Bonomo L.,
Del Grande F.,
Casiraghi M.,
De Marinis F.,
Spaggiari L.
Type
Journal Article
Year
2023
Language
English
Abstract
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.
Keywords
Lung cancer, Stage III, Surgery, Medical treatment, Radiotherapy
Journal
Current oncology
Volume
30
Number ( Month )
3
Pages (or article number)
3160-3175
Diffusion
License
CC BY
Visibility
Public
Status open access
Gold
